By contrast, pegylated interferon-α (Peg-IFNα) has shown efficacy in controlling thrombocytosis, reducing spleen size, and improving symptom burden [76,77], with notable molecular responses, particularly in JAK2 V617F–mutated cases. This evidence concerns the gene JAK2 and Thrombocytosis.